|
 |
| home > ebr > spring 2004 > allergen microarrays: a novel tool for improved target discovery and individualised therapy |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| In recent years, protein microarrays have emerged as a key novel technology in the field of proteomics. Based on the concept of miniaturised ligand interaction assays, microarray-based immunological tests bear a great potential for high-throughput-based protein profiling, target finding and diagnostic applications. The use of allergens in recombinant and purified form has brought with it the introduction of allergen-specific IgE testing to the microarray format. Here, we discuss the application of microarray-based allergen profiling in the field of allergy vaccine development and its resulting impact on state-of-the-art diagnostic approaches. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
